DongKoo Bio&Pharma

Picoentech is a biotechnology company focused on developing innovative solutions to improve health and delay aging through its proprietary ARC (Accumulated-aldehyde Reducing Compounds) technology. The company specializes in detox enzyme technology, employing a fermentation process to create treatments that help maintain healthy skin and remove toxins from the body. By addressing the accumulation of harmful substances, Picoentech aims to enhance overall well-being and promote a healthier lifestyle for its patients.

Qurient Co., Ltd. is a South Korean biotechnology company founded in 2008 that focuses on researching and developing innovative drugs to meet unmet medical needs. The company employs a unique "Network R&D" model, which integrates research and drug development through a collaborative network of experts. Qurient's product pipeline includes Q301, aimed at treating atopic dermatitis; Q203, designed for drug-resistant tuberculosis; and Q701, which targets drug-resistant cancer in immuno-oncology. Additionally, the pipeline features a 5LO inhibitor for asthma and a CDK7 inhibitor for cancer. Since its inception, Qurient has positioned itself at the forefront of the emerging biotech industry in Korea, emphasizing efficient innovation across various therapeutic areas.

Verismo Therapeutics is a biotechnology company focused on developing innovative chimeric antigen receptors (CARs) to enhance T-cell-based immunotherapy for cancer treatment. Their proprietary cellular therapy, known as KIR-CAR, aims to provide a natural stimulation to T cells while preventing T-cell exhaustion, which is a common challenge in cancer therapies. The company is currently advancing its lead therapy candidates in preclinical development, specifically targeting solid tumors such as pancreatic cancer, mesothelioma, and ovarian cancer. By extracting white blood cells from patients, genetically modifying them to specifically target cancer cells, and then reintroducing them into the patient, Verismo Therapeutics seeks to improve the persistence and efficacy of these treatments against solid tumor models.

Valted Seq is a discovery-stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of therapeutics for neurodegenerative diseases. The company focuses on identifying neurodegenerative pathways and biomarkers to enhance the creation of innovative therapeutics and diagnostics, including companion diagnostics that support advanced treatments. Valted Seq has established the world's largest repository of single-cell sequencing data derived from high-quality, clinically characterized brain tissues of patients suffering from conditions such as Alzheimer's and Parkinson's diseases. This extensive database enables the company to inform and accelerate the development of precision therapeutics, ultimately improving patient access to advanced medical interventions.

Vuno Inc. is a South Korean company specializing in the development of artificial intelligence solutions for the medical field. Founded in 2014, Vuno focuses on creating AI-based products that assist healthcare professionals in analyzing medical data and diagnosing diseases. Its notable offerings include BoneAge, which assesses bone age, DeepBrain, designed for the analysis of neurodegenerative diseases, and a chest X-ray diagnostic support system. Additionally, Vuno provides fundus AI for eye abnormalities and LungCT AI for detecting and reporting pulmonary nodules. The company serves a range of clients, including Asan Medical Center and HYUNDAI, and also offers VunoMed, a platform for analyzing various medical data types, including videos, ECGs, and electronic medical records.

Neuraly, Inc. is a clinical-stage biotechnology company based in Germantown, Maryland, focused on discovering and developing innovative treatments for neurodegenerative diseases, including Parkinson's and Alzheimer's diseases. Founded in 2016, Neuraly emerged from research conducted by leading neuroscientists, notably Ted Dawson at Johns Hopkins School of Medicine. The company is known for its neuroprotective agent NLY01, which targets the pathological activation of microglia, and also develops two blood-brain barrier-penetrating kinase inhibitors, NLY02 and NLY03. Neuraly's approach emphasizes the crucial role of glial cells in neurodegenerative disease progression, aiming to prevent neuronal cell death and enhance the quality of life for affected individuals.

D&D Pharmatech Co., Ltd., established in 2014 and headquartered in Seongnam, South Korea, is a clinical-stage global biotech company specializing in developing innovative medicines. It focuses on various therapeutic areas, including neurodegenerative diseases, molecular imaging and radiotherapy, fibrotic diseases, and metabolic diseases. The company operates through disease-specific subsidiary companies guided by top-tier medical research faculty, aiming to accelerate the translation of cutting-edge research into lifesaving therapeutic products for patients. D&D Pharmatech's product pipeline is supported by its team of experts in bio-new drug research and development, manufacturing quality control, clinical development, and technology transfer. Additionally, it develops positron emission tomography (PET) imaging biomarkers through Precision Molecular Inc., a wholly-owned subsidiary, and conducts single-cell sequencing related to degenerative brain diseases via Valted Seq, Inc. The company employs technologies such as PEGylation to extend drug administration periods.